|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4761 - 0.4761|
|52 Week Range||0.2130 - 0.8820|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC, Sept. 17, 2020 /CNW/ - The following issues have been halted by IIROC:Company: Canntab Therapeutics LimitedCSE Symbol: PILL All Issues: YesReason: At the request of the Company Pending NewsHalt Time (ET): 9:34 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.
TORONTO, Aug. 21, 2020 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.
TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.